austin… not host :)

Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.
In the study, published online in the Journal of Clinical Oncology, researchers found that in a group of 12,677 men who had radical prostatectomies between 1987 and 2005, the fifteen-year mortality rate that could be directly linked to prostate cancer was only 12 percent, even though many of the patients’ cancers had aggressive features. Comparatively, the rate of non- cancer-related death in this group was 38 percent. A small fraction, 4 percent, of patients treated surgically within the past ten years had a 5 percent or greater risk of dying of prostate cancer within 15 years. It is not clear at this time whether the outcomes may be related to the effectiveness of surgery and any secondary therapy, or to the low lethality of certain types of prostate cancers to begin with.
"The importance of this paper is that it shows a remarkably low risk of dying of prostate cancer within 15 years for treated men, and supports the concept that men with slow-growing cancers may not need immediate treatment," said senior author Peter Scardino, Chair of the Department of Surgery at MSKCC. "Further good news is that surgery was very effective in preventing death in men with aggressive cancers–defined as those with a high PSA, poorly differentiated with a Gleason grade of 8-10, or locally extensive," Dr. Scardino added.
Not all prostate cancers progress the same way. Many cancers pose little or no threat to life and health, while others grow aggressively and are resistant to treatment. Buy generic neurontin The key is to determine which cancers are "favorable" or ones likely to remain relatively dormant. According to Dr. Scardino, "Currently, there are a number of tools physicians have to help determine the probable course of prostate cancer, but more accurate ones are needed."
Dr. Scardino and colleagues have formulated and pioneered the use of validated statistical models, or nomograms, that help predict the natural progression of prostate cancer and how it will respond to treatment. These nomograms help tailor treatment for men according to the specific characteristics of their cancer. The prostate cancer nomograms are currently the most widely used, disease-specific prediction tool in oncology.
In addition to the nomogram, physicians may use PSA testing, Gleason grade, MRI scans, and multiple biopsies to determine which cancers are likely to be favorable and which are not. While there are tools and models available now to help predict survival, Dr. Scardino and his fellow authors encourage future research to pinpoint better markers specifically associated with the biology of lethal prostate cancer.
"In the future, what we’d like is to be able to do a molecular or genetic analysis of prostate tumor cells to see if they have the capacity to spread, so that we can ask, does your tumor have that capacity? If not, it would be safe to watch," said Dr. Scardino.
As part of the study, 12,677 patients treated with radical prostatectomy between 1987 and 2005 were tracked. Of these patients, 6,398 underwent radical prostatectomy for localized prostate cancer at either MSKCC or Baylor College of Medicine, with 809 (13%) receiving neoadjuvant androgen-deprivation therapy for an average of 3.2 months. External validation of the nomogram was performed on 4,103 patients treated at Cleveland Clinic and 2,176 patients treated at University of Michigan during the same period.
Prostate biopsy specimens were reviewed by pathologists at each institution before surgery. In general, patients were followed for disease recurrence post operatively with regular PSA tests and clinical exams at three to six month intervals for the first five years, and then annually. The year of surgery was also a consideration, as methods and effectiveness have changed over the years.
While prostate cancer death rates have been dropping over the past decade, according to the American Cancer Society, it is estimated that there were 186,320 new cases of prostate cancer in the United States in 2008 and 28,660 deaths from the disease.
Tags: Cancer, Oncology, Prostate Cancer, Prostate-Specific Antigen, Radical Prostatectomy
USA’s largest ever prostate cancer screening program shows high compliance and consistent resultsJust under five per cent of the men who took part in the prostate cancer element of the USA’s larges…Research shows mobile phones raise children’s risk of brain cancer by five timesNew research from Sweden is certain to alarm many as it has found that young people today are five t…Generic prostate drug finasteride helps find high-risk cancers earlyMen now have another good reason to consider taking finasteride, a well-known generic drug that shri…Promising new treatment options for prostate cancerProstate cancer is the second leading cause of death among American men. It is estimated that one in…Diffusion MRI gives early indication if brain cancer therapy is effectiveA special type of MRI scan that measures the flow of water molecules through the brain can help doct…
The opinions expressed here are the views of the writer and do not necessarily
reflect the views and opinions of News-Medical.Net. The information on this site
is not intended or implied to be a substitute for professional medical advice,
diagnosis or treatment. Always seek the advice of a qualified medical professional.
Hong Kong S.A.R.
Macao S.A.R.
U.A.E.

Alzheimer’s Disease Biotechnology Brain Cancer Cardiovascular Disease Diabetes Diet DNA Genetics Genomics Global Health Aid H1N1 Health Insurance Health IT Health Reform HIV/AIDS Hospital Immunology Influenza Malaria Maternal Health Medicaid Medical Legislation Medicare Nanotechnology Neurology Nutrition Obesity Oncology Pandemic Pediatrics Pregnancy Prescription Drug Prostate Cancer Stroke Swine Flu Taxation Tuberculosis Vaccine Virus
Finance committee may omit public plan, employer mandateAMA backs health reform plan, but not all doctors are on boardReform could hinge on the insured, who support reform but fear changeDemocrats to push unscored benefits to counter latest CBO analysisSubsidies to cover uninsured critical to health overhaulObama health reform proposals and alliances scrutinizedHouse members continue bickering over reformSenate Dems seek compromise on contentious health reform issuesAs they debate health overhaul, politicians keep eye on 2010Health care legislation’s hurdles and potential impacts
Generic neurontin pills no prescription | Generic viagra pills no prescription | Buy cipro pills

Tags: finasteride, obesity

Comments are closed.